Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. (NASDAQ: GDRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a digital healthcare and medication savings platform. These SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits covering executive compensation, director arrangements, and key commercial developments.
In its earnings-related Form 8-K filings, GoodRx furnishes press releases that discuss revenue from prescription transactions, subscriptions, and pharma manufacturer solutions, as well as non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income. These documents also describe capital allocation priorities, including investing for growth, debt repayment, share repurchases, and mergers and acquisitions that align with the company’s strategy.
Other 8-K filings provide detail on governance and compensation matters. For example, GoodRx has reported retention bonus agreements for certain executives, including the structure of cash retention bonuses and repayment conditions tied to employment status. It has also disclosed the transition of an executive officer to a non-employee director role, outlining standard non-employee director compensation, committee retainers, and restricted stock unit awards under its non-employee director compensation program and deferred compensation plan.
Through this page, users can access GoodRx’s SEC filings as they are made available via EDGAR. AI-powered summaries on the platform help explain the contents of complex documents, including 10-K and 10-Q reports, by highlighting key themes such as segment performance, prescription transactions trends, subscription and pharma manufacturer solutions growth, and risk factor disclosures. Filings related to insider and director compensation, as well as current reports on material events, are also accessible, giving investors and researchers a structured view of how GoodRx manages its business, governance, and financial reporting obligations.
GoodRx Holdings, Inc. describes its business model as a consumer-focused digital healthcare platform that helps Americans find lower prices on prescription drugs and related services. The company’s core prescription transactions offering still generates most revenue, complemented by subscriptions, telehealth and pharma-direct advertising solutions.
GoodRx highlights a large estimated prescription and pharma-direct market opportunity of $600–$710 billion and positions its data-driven pricing engine, PBM and pharmacy relationships, and brand as key advantages. The filing also outlines significant risks, including PBM and retail pharmacy concentration, store closures, new federal initiatives like TrumpRx.gov, regulation of data privacy and telehealth, shifting cost burdens to consumers, and execution challenges as it expands offerings and manages growth.
GoodRx Holdings, Inc. reported fourth quarter 2025 revenue of $194.8 million and full year 2025 revenue of $796.9 million, up slightly from 2024. Full year net income rose to $30.4 million with a 3.8% net margin, while Adjusted EBITDA reached $270.5 million and a 33.9% margin. Growth was driven by a 41% increase in 2025 Pharma Direct revenue to $151.4 million, partly offset by declines in prescription transactions and subscription revenue. The company generated $167.9 million in operating cash flow, ended 2025 with $261.8 million in cash and $495.0 million of total debt, and repurchased 48.9 million Class A shares for $217.4 million. For 2026, management guides revenue to $750–$780 million and Adjusted EBITDA of more than $230 million, implying a year-over-year decline in both metrics while maintaining strong profitability.
McGinnis Christopher A reported multiple insider transaction types in a Form 4 filing for GDRX. The filing lists transactions totaling 411,039 shares at a weighted average price of $2.18 per share. Following the reported transactions, holdings were 537,359 shares.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported equity award activity involving Class A common stock. On February 15, 2026, Nabiey exercised 4,804 restricted stock units, converting them into the same number of Class A shares at an exercise price of $0. In a related transaction coded "F," 1,979 Class A shares at $2.18 per share were disposed of to cover tax obligations, leaving 175,748 Class A shares held directly and 57,650 restricted stock units outstanding after these transactions.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported RSU vesting and related share movements. On February 8, 2026, 12,663 restricted stock units converted into 12,663 shares of Class A common stock at an exercise price of $0.
On the same date, a Form 4 code “F” transaction reported the disposition of 5,215 Class A shares at $2.44 per share. Following these transactions, Nabiey beneficially owned 172,923 Class A common shares directly and 63,314 restricted stock units, each representing a right to receive one Class A share.
GoodRx Holdings director Scott Wagner reported the vesting of deferred stock units and corresponding common stock on January 21, 2026. A deferred stock unit award vested for 31,394 units, which corresponds to 31,394 shares of Class A common stock at an exercise price of $0. After this transaction, Wagner directly beneficially owned 62,788 deferred stock units and 216,663 shares of Class A common stock. The deferred stock units will settle in shares on the earliest of December 31, 2030, separation from service, a change in control, death, or disability, under the company’s Deferred Compensation Plan for Directors.
GoodRx Holdings director and officer Wendy Lynn Barnes reported equity compensation activity involving restricted stock units and Class A common stock on January 15, 2026. A total of 665,302 restricted stock units were converted into the same number of Class A shares at an exercise price of $0.00 per share.
To cover tax obligations, 148,383 shares and 88,926 shares of Class A common stock were withheld at a price of $2.75 per share, reducing the net shares retained. After these transactions, Barnes directly beneficially owned 427,993 shares of GoodRx Class A common stock. Footnotes explain that each restricted stock unit represents a contingent right to receive one Class A share and outline multi-year vesting schedules for the awards.
GoodRx Holdings, Inc. disclosed that its board approved retention bonus letter agreements for Chief Executive Officer and President Wendy Barnes and Chief Financial Officer and Treasurer Chris McGinnis on December 9, 2025. Through these agreements, Ms. Barnes is eligible for a cash retention bonus of $2,000,000 and Mr. McGinnis for $1,000,000, each payable within 15 days after signing.
The bonuses must be repaid if employment ends either by the executive without "good reason" or by the company for "cause": 100% of the after-tax bonus if termination occurs on or before December 31, 2026, or 50% if termination occurs between January 1, 2027 and December 31, 2027. In exchange, both executives will forfeit any payment under the company’s 2025 executive bonus plan and any other 2025 annual cash incentive or discretionary bonus program. The full agreements are filed as Exhibits 10.1 and 10.2.
GoodRx Holdings, Inc. officer Romin Nabiey, the Chief Accounting Officer, reported equity transactions dated December 8, 2025. He acquired 10,200 and 2,232 shares of Class A common stock through the vesting and settlement of restricted stock units and disposed of 3,650 and 799 shares at $2.71 per share.
After these transactions, Nabiey directly beneficially owns 165,475 shares of Class A common stock. He also continues to hold restricted stock units representing 30,603 and 20,091 underlying shares, which vest 6.25% initially and then in approximately equal quarterly installments over 15 quarters starting on December 8, 2022 and June 8, 2024, respectively.
GoodRx Holdings, Inc. (GDRX) Chief Accounting Officer Romin Nabiey reported equity award activity on 11/15/2025. He acquired 4,804 shares of Class A common stock upon the vesting and settlement of restricted stock units and then disposed of 1,719 shares at $2.97 per share, typically used to cover taxes. Following these transactions, he directly held 156,492 Class A shares.
The underlying restricted stock unit grant covers 4,804 shares. It vests as to 6.25% of the underlying shares on May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over the next 15 quarters.